This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
Annals of Hematology Open Access 08 August 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857–877.
Rubio MT, Boumendil A, Luan JJ, Canals C, Lefrere F, Attal M et al. Is there still a place for total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: a retrospective study from the lymphoma working party of the EBMT. Blood (ASH Annual Meeting Abstracts) 2010; 116, abstract 688.
Peterlin P, Leux C, Gastinne T, Roland V, Mahe B, Dubruille V et al. Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients? Transplantation 2012; 94: 295–301.
Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia 2015; 29: 464–473.
Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693.
Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355–362.
van 't Veer MB, de Jong D, MacKenzie M, Kluin-Nelemans HC, van Oers MH, Zijlstra J et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009; 144: 524–530.
Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger trial of the European Mantle Cell Lymphoma Network (MCL net). ASH Annual Meeting Abstracts 2010; 116: abstract 110.
Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger trial of the European Mantle Cell Lymphoma Network (MCL net). ASH Annual Meeting Abstracts 2012; 120: abstract 151.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253.
Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558–565.
Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A et al. Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol 2014; 32: 1338–1346.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
WK has received grants and travel reimbursement from Roche, Celgene, Janssen, Novartis and Takeda/Millenium not related to the project and paid to the institution. All other authors declare no competing financial interests.
Additional information
Author contributions
EH, CHG, JD, MU, MD and OH designed and performed research, CHG, JD, BvdH, JW, JB, VR, GS, MH, CP, MS, AK, AL, RR, MJ, MvV, JCK-N, WK, MU, MD and OH acquired data, EH performed statistical analysis and drafted the manuscript, EH, CHG, MD and OH interpreted data, all authors revised the manuscript and approved the final version of the manuscript.
Rights and permissions
About this article
Cite this article
Hoster, E., Geisler, C., Doorduijn, J. et al. Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. Leukemia 30, 1428–1430 (2016). https://doi.org/10.1038/leu.2015.322
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.322
This article is cited by
-
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
Annals of Hematology (2023)
-
Hematopoietic cell transplantation for mantle cell lymphoma
International Journal of Hematology (2022)
-
Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma
Bone Marrow Transplantation (2018)